{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-005515","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.223918+00:00","generated_at":"2026-06-11T17:23:16.413626+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Phio Pharma Q2 net loss $2.5M; PH-762 Phase 1b trial advancing after IND clearance","bullets":["Net loss of $2.5M ($1.47 per share) for Q2 2023, consistent with $2.5M ($2.22 per share) in Q2 2022.","Cash $11.3M at June 30, 2023 vs $11.8M at Dec 31, 2022; R&D expenses $1.4M, up 6% YoY.","FDA cleared IND for PH-762; planning Phase 1b trial for cutaneous squamous cell carcinoma, melanoma, Merkel cell.","Initiated collaborative Phase 1b trial with AgonOx's TIL program (AGX148) and Providence Cancer Institute.","Appointed Jennifer Phillips, Pharm.D., as VP of Regulatory Affairs and Corporate Affairs."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-005515","json":"https://secwatch.observer/filing/0001683168-23-005515.json","markdown":"https://secwatch.observer/filing/0001683168-23-005515.md","text":"https://secwatch.observer/filing/0001683168-23-005515.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000168316823005515/0001683168-23-005515-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000168316823005515/phio_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T17:23:16.413626+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0bb07e25bd1c5cd64ee5bdaeee6121d8ad939867","claim":"Phio Pharmaceuticals Corp. reported quarter ended June 30, 2023 results: net income $2.5 million, or $1.47 per share.","evidence_excerpt":"Net loss was $2.5 million, or $1.47 per share, for the quarter ended June 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533040/000168316823005515/0001683168-23-005515-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended June 30, 2023"},{"label":"Net income","value":"$2.5 million, or $1.47 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}